Resistance to immune-checkpoint blockade often occurs in treated patients. Here, the authors demonstrate that B2M loss is a mechanism of primary and acquired resistance to therapies targeting CTLA4 or PD-1 in melanoma patients.
- Moshe Sade-Feldman
- Yunxin J. Jiao
- Nir Hacohen
